SCHEMBL2144707

SCHEMBL2144707

Nc1ccc2c(c1)CN(C(=O)O)C2=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 1/20 0.44
HSD17B10 Q99714 4/20 0.43
CASP1 P29466 3/20 0.43
CASP7 P55210 2/20 0.43
HSD17B3 P37058 1/20 0.41
MAPT P10636 4/20 0.41
LMNA P02545 3/20 0.41
GAA P10253 2/20 0.41
KDM4E B2RXH2 5/20 0.41
ALDH1A1 P00352 5/20 0.41
HPGD P15428 2/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
CYP2D6 P10635 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
HTT P42858 1/20 0.38
MAOB P27338 1/20 0.36
RAB9A P51151 6/20 0.36
NPC1 O15118 5/20 0.36
BRD4 O60885 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3304740 0.87 ALDH1A1 (0.53) CRBNHSD17B10CASP1CASP7HSD17B3
SCHEMBL2144912 0.80 SDCBP (0.48) HSD17B3BRD4
SCHEMBL18786921 0.78 NR1H2 (0.54) CRBNHSD17B10CASP1CASP7HSD17B3
SCHEMBL15169553 0.76 METAP1 (0.45) HSD17B10GAAKDM4EALDH1A1HPGD
SCHEMBL18939965 0.76 LMNA (0.39) MAPTLMNAKDM4EHPGDSMN1; SMN2
SCHEMBL29606824 0.75 KDM4E (0.57) HSD17B10MAPTLMNAGAAKDM4E
SCHEMBL2065531 0.75 KDM4E (0.57) HSD17B10MAPTLMNAGAAKDM4E
SCHEMBL18940077 0.75 LMNA (0.39) LMNAKDM4EALDH1A1SMN1; SMN2HTT
Hydrochloric Acid SCHEMBL11289267 0.74 KDM4E (0.55) HSD17B10MAPTLMNAGAAKDM4E
SCHEMBL2144936 0.74 CASP1 (0.47) CRBNHSD17B10CASP1CASP7MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018136935-A1 2-ARYLSULFONAMIDO-N-ARYLACETAMIDE DERIVATIZED STAT3 INHIBITORS UNIVERSITY OF HAWAII (US) 2018-07-26 WO disclosed
EP-2344494-B1 AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS SIGNAL PHARM LLC (US) 2016-04-20 EP disclosed
US-20130005707-A1 AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BAHMANYAR SOGOLE (US) 2013-01-03 US disclosed
US-8299056-B2 Aminotriazolopyridines, compositions thereof, and methods of treatment therewith SIGNAL PHARMACEUTICALS, LLC (US) 2012-10-30 US disclosed
EP-2344494-A1 AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS Signal Pharmaceuticals, LLC (US) 2011-07-20 EP disclosed
US-20100093698-A1 AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2010-04-15 US disclosed
WO-2010027500-A1 AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS SIGNAL PHARMACEUTICALS, LLC (US) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005707-A1 AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH MAP3K2, MAP3K1, MAP3K3 CRBN 1475/4885HSD17B10 2492/4885CASP1 490/4885
US-20100093698-A1 AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH MAP3K2, MAP3K1, MAP3K3 CRBN 1475/4885HSD17B10 2492/4885CASP1 490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.